SteadyMD vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
SteadyMD built B2B telehealth infrastructure with 600+ clinicians in 50 states (~5M revenue); acquired by DocGo (Oct 2025) to become the clinical backend for digital health platforms.
About
SteadyMD was founded in 2016 in St. Louis with a mission to build the infrastructure layer that enables healthcare companies to deliver telehealth services without building clinical operations from scratch. The company recognized that the fastest-growing segment of the telehealth market was not direct-to-consumer care but B2B infrastructure — the clinical staffing, licensing, credentialing, compliance, and workflow systems that other healthcare companies need to operate virtual care programs at scale. SteadyMD built this stack as a managed service, enabling digital health companies, health systems, and employers to launch and scale telehealth programs rapidly.\n\nSteadyMD's platform provides healthcare organizations with access to a network of more than 600 clinicians — physicians, nurse practitioners, and physician assistants — who are licensed across all 50 states and available for virtual care delivery. Clients integrate SteadyMD's clinical workforce and telehealth operating system into their own products, using SteadyMD as an outsourced clinical operations partner rather than building in-house clinician networks. This white-label infrastructure model serves clients across consumer health, chronic disease management, occupational health, and behavioral health — wherever organizations need scalable, compliant clinical capacity without the overhead of direct employment.\n\nSteadyMD was acquired by DocGo in October 2025, a publicly traded mobile health and medical transportation company, in a transaction that brings SteadyMD's telehealth infrastructure capabilities under a larger multimodal healthcare services platform. Prior to the acquisition, SteadyMD generated approximately $25 million in annual revenue, demonstrating durable commercial traction in the B2B telehealth infrastructure segment. The DocGo acquisition positions SteadyMD's technology and clinician network as a foundation for DocGo's expansion into virtual care delivery, combining telehealth infrastructure with DocGo's existing in-person mobile health operations.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.